﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Nickan Research Institute</PublisherName>
      <JournalTitle>Journal of Renal Injury Prevention</JournalTitle>
      <Issn>2345-2781</Issn>
      <Volume>2</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2013</Year>
        <Month>06</Month>
        <DAY>20</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Current concepts on anti-Phospholipase A2 receptor antibody in Idiopathic membranous nephropathy</ArticleTitle>
    <FirstPage>71</FirstPage>
    <LastPage>72</LastPage>
    <ELocationID EIdType="doi">10.12861/jrip.2013.23</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mohammad Reza</FirstName>
        <LastName>Ardalan</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.12861/jrip.2013.23</ArticleId>
    </ArticleIdList>
    <History>
    </History>
    <Abstract>Implication for health policy/practice/research/medical education:Phospholipase A2 receptor, is normally expressed in podocyte membrane. In fact the phospholipase A2 receptor (PLA2R) is a type I transmembrane glycoprotein related to the C-type animal lectin family such as the mannose receptor. PLA2R regulates a number of biological responses produced by secretory phospholipase A2s (sPLA2s). Determining anti-PLA2r serum levels in patients with nephrotic syndrome should designate a probable diagnosis of idiopathic membranous nephropathy and in patients in which idiopathic membranous nephropathy had a pathology confirmation may be a determining factor to exclude secondary forms of the disease. However, it is too early to abandon a kidney biopsy in patients with nephritic syndrome, and PLA2R as the newly introduced serologic study needs confirmations to finds its proper place in the field of clinical medicine.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Membranous nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nephrotic syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phospholipase A2 receptor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anti-PLA2R antibody</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>